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Abstract
Background: The silent progression of chronic kidney diseases (CKD) and its association with other chronic
diseases, and high treatment costs make it a great public health concern worldwide. The population burden of CKD
in Peru has yet to be fully described.
Methods: We completed a cross sectional study of CKD prevalence among 404 participants (total study population
median age 54.8 years, 50.2 % male) from two sites, highly-urbanized Lima and less urbanized Tumbes, who were
enrolled in the population-based CRONICAS Cohort Study of cardiopulmonary health in Peru. Factors potentially
associated with the presence of CKD were explored using Poisson regression, a statistical methodology used to
determine prevalence ratios.
Results: In total, 68 participants (16.8 %, 95 % CI 13.5–20.9 %) met criteria for CKD: 60 (14.9%) with proteinuria, four
(1%) with eGFR <60mL/min/1.73m2 , and four (1%) with both. CKD prevalence was higher in Lima (20.7 %, 95 % CI
15.8–27.1) than Tumbes (12.9 %, 95 % CI 9.0–18.5). Among participants with CKD, the prevalence of diabetes and
hypertension was 19.1 % and 42.7 %, respectively. After multivariable adjustment, CKD was associated with older
age, female sex, greater wealth tertile (although all wealth strata were below the poverty line), residence in Lima,
and presence of diabetes and hypertension.
Conclusions: The high prevalence rates of CKD identified in Lima and Tumbes are similar to estimates from
high-income settings. These findings highlight the need to identify occult CKD and implement strategies to prevent
disease progression and secondary morbidity.
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Background
Owing to the rising global epidemic of diabetes [1],
hypertension [2], and obesity [3], chronic kidney disease
(CKD) has become a worldwide public health problem
with a substantial economic burden. For instance, the
World Health Organization estimated a high cost-
effectiveness ratio for dialysis, roughly $108,600 USD
per disability-adjusted life-year [4, 5]. CKD further in-
creases diabetes and hypertension-related complications,
including cardiovascular risk and all-cause mortality
[4, 6, 7]. In addition, due to major constraints on the
availability of healthcare resources, CKD may impose a
tougher challenge on low- and middle-income coun-
tries (LMIC). Understanding the epidemiology of CKD
in LMIC is a fundamental step to addressing the bur-
den of CKD and will guide disease surveillance, screen-
ing, prevention activities as well as healthcare resource
allocation.
Given its diverse range of socio-economic trends and
climatic and geographical zones, Peru provides a unique
opportunity in which to assess CKD burden [8]. In 2013,
approximately 65 % of the Peruvian population has some
form of health insurance [9], but only an estimated 30 %
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of all Peruvians are able to access renal replacement ther-
apy [10]. Another emerging challenge to current vulner-
able health systems in Peru is its rapid population
growth, which is reflected by changes in age structure
and urbanization [11, 12]. However, as Peru is experien-
cing a marked demographic and epidemiologic transi-
tion with a rising prevalence of cardiovascular disease
risk factors such as obesity, hypertension and type-2
diabetes, related illnesses such as CKD are also likely to
be rising in prevalence [13, 14]. This scenario highlights
the importance of detection of CKD and implementa-
tion of interventions that stem its progression toward
end-stage disease.
In Peru, as in many other countries in Latin America,
the information related to the epidemiology of CKD and
end-stage renal disease is limited. Early hospital-derived
data from 1990 suggested the prevalence of CKD in
Lima to be only 12.2/100,000 people [15]. Since 1991,
the Latin American Dialysis and Renal Transplant Regis-
try has collected data from 20 countries and reported a
high utilization of renal replacement therapy [16]. These
data suggest that the burden of CKD has been under-
appreciated and the need to design CKD surveillance
programs as well as appropriate end-stage renal disease
management [17, 18].
The CRONICAS cohort study is a general population-
based longitudinal study in Peru assessing cardiopulmonary
risk factors [19]. This study examined CRONICAS study
participants identified at two of the three study sites, Lima
and Tumbes (Fig. 1), to estimate the prevalence of CKD
and its potential risk factors.
Methods
Study design and setting
This cross-sectional study collected baseline CKD marker
data in a random subsample of the ongoing CRONICAS
cohort study [19]. Data were collected from February to
May 2011 in the highly-urbanized site of Pampas de San
Juan de Miraflores, Lima, Peru with 60,000 inhabitants in
4 km2, and the semi-urban site of Tumbes with 20,000 in-
habitants in 80 km2. Lima, the country’s capital, is located
in the central west coast region of Peru and Tumbes is
located along the northwest coastline. Both regions have
undergone different degrees of urbanization, including
urban-industrial development [20].
Participants, recruitment, and ethics
Using the most updated local census data, study partic-
ipants were identified using a single-stage sampling
method stratified by sex and age (35–44; 45–54; 55–
Fig. 1 Map of study sites in Peru. Copyright permission. One of the authors (C-CK) created this image using ConceptDraw PRO software
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64; ≥ 65 years old) [19]. Participants were included if
they were full-time residents in the area, capable of
understanding the study’s procedures, and able to pro-
vide informed consent. Patients were excluded if they
were pregnant or unable to sit upright or lay down,
precluding measurement acquisition. Participants were
selected until each age and sex category was filled.
Only one member per household was enrolled in the
study.
Trained fieldworkers went door-to-door to contact se-
lected participants. After discussing the parent study
protocol and receiving informed consent, participants
were scheduled to gather anthropometric measurements.
At this appointment, a sub-sample of participants were
approached and invited to participate in the CKD ancil-
lary study and enrolled after obtaining verbal informed
consent. The study’s protocol was reviewed and approved
by the Institutional Review Boards of Universidad Peruana
Cayetano Heredia and University of Pennsylvania.
Data collection
The protocol for the CRONICAS Cohort Study has been
published elsewhere [19]. Briefly, each participant com-
pleted a fieldworker-administered questionnaire to pro-
vide information on socio-demographic and lifestyle
data including age, sex, education level, work status, al-
cohol consumption, smoking habits, previous medical
history, and medication use. The questionnaire was
based on the STEPS approach for surveillance of non-
communicable diseases [21]. Trained fieldworkers mea-
sured height and weight from all participants during the
clinic visit [19]. Each measurement was taken three
times, and the average of the three was used for analyses.
In addition, three systolic (SBP) and diastolic (DBP)
blood pressure measurements were acquired using an
automated monitor (OMRON HEM-780) [19]. The
second and third blood pressure measurements were
averaged for the analysis.
A trained laboratory technician obtained fasting
venous blood and urine samples. Whole blood and
plasma were collected in ethylenediaminetetraacetic acid
(EDTA) tubes and sodium fluoride/EDTA tubes, respect-
ively. Urine was collected in 15 mL containers. Blood
serum and urine specimens were maintained at 4–8 °C
for two weeks and then moved to a storage facility
where the urine was aliquoted into 4 vials (1.5 mL each).
All samples were then stored at −20 °C until laboratory
analyses were performed. All samples were analyzed in a
single laboratory. Assay quality was checked against
regular external standards and internal duplicate assays
and monitored by BioRad (http://www.biorad.com).
Details pertaining to the measurement of plasma glucose,
serum insulin, hemoglobin A1C, total cholesterol and high-
density lipoprotein (HDL)-cholesterol are outlined in the
parent study protocol. [18] High-sensitivity C reactive
protein was measured using Latex (Tina-quant CRP-HS
Roche/Hitachi analyzer, Indianapolis, IN, USA). Serum and
urine creatinine were measured by the modified kinetic
Jaffé method. The enzymatic method was standardized to
the IFCC’s isotope dilution mass spec (IDMS) method.
Urine protein was determined via turbidimetry as
measured by the Sequoia-Turner digital fluorometer.
Study variables
The glomerular filtration rate, a measure of kidney
function, was estimated using the CKD-Epidemiology
Collaboration equation using serum creatinine as a fil-
tration marker [22]. To ensure consistency across stud-
ies, CKD was defined as estimated glomerular filtration
rate (eGFR) <60 ml/min/1.73 m2 or proteinuria (pro-
tein-creatinine ratio) ≥150 mg/g creatinine, or both,
based on the latest Kidney Disease Improving Global
Outcomes (KDIGO) guideline [4].
Diabetes mellitus was defined as fasting plasma glucose
≥126 mg/dL or self-reported physician diagnosis or use of
anti-diabetic medications [23]. Hypertension was defined
as a systolic blood pressure (SBP) of ≥140 mmHg, a
diastolic blood pressure (DBP) of ≥90 mmHg, receipt
of anti-hypertensive therapy at the time of enrollment,
or self-report of a diagnosis by a physician [24].
Insulin resistance was assessed using the homeostasis
model assessment (HOMA-IR) originally described by
Mathew et al. [25] The Framingham risk score (FRS)
was calculated from National Cholesterol Education Pro-
gram (NCEP) Adult Treatment Panel (ATP) III algo-
rithm and based on six cardiovascular risk factors: age,
gender, total cholesterol, HDL-cholesterol, systolic BP
and smoking status [26]. A 10-year risk of coronary
events was divided into three levels of risk: low (<10 %),
intermediate (10–20 %), and high (>20 %) [26].
Socioeconomic status was assessed using a wealth
index based upon current occupation, household in-
come, assets and household facilities [27]. Smoking was
categorized as current, former, or never. Alcohol con-
sumption was categorized into non-current and current
drinkers. Body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared.
Statistical analysis and model selection
Categorical variables were described as proportions, and
continuous variables were described as median with
interquartile range (IQR). Differences between CKD and
non-CKD participants were examined using Chi-square
tests for categorical variables or Student t-tests for con-
tinuous variables. Both eGFR and protein-creatinine ra-
tio were right skewed and, thus, log-transformed for
linear regression. The 2-sided statistical significance level
was set at α = 0.05.
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Multivariate Poisson regression was performed to calcu-
late prevalence ratios [28] and to assess the relationship
between CKD and associated potential risk factors. These
models were initially adjusted for sociodemographic and
lifestyle variables including age, education, smoking
habits, alcohol consumption and BMI, followed by adjust-
ments for comorbidities including diabetes mellitus,
hypertension, and C-reactive protein. Exploratory analyses
were conducted within subgroups of the following covari-
ates: age, sex, obesity, smoking, alcohol, total cholesterol,
hypertension, diabetes mellitus, and Framingham risk
score. All statistical analyses were conducted using
STATA version 11.0 statistical software (StataCorp LP,
College Station, TX, USA). It should be noted that exact
logistic regression was also used to for univariate analysis




The overall participation rate in the CRONICAS parent
study was 62.9 %. A total of 404 adults, mean age
54.9 years [SD 13.0], 50.2 % male, were invited and
agreed to participate in this sub-study of CKD. All 404
participants, 203 from Lima and 201 from Tumbes,
completed a questionnaire, a clinical examination and la-
boratory tests. Overall, the prevalence of diabetes and
hypertension were 9.9 % (40/404, 95 % CI 7.4–13.3 %)
and 29.2 % (118/404, 95 % CI 25.1–34.0 %), respectively.
Prevalence chronic kidney disease
The prevalence of CKD was 16.8 % (68/404, 95 % CI
13.5 %–20.9 %). Participants with CKD tended to be
older, female (69.1 %), consumers of alcohol (98.5 %),
less educated, and with more comorbid conditions, in-
cluding diabetes and hypertension (Table 1).
Among the 68 participants meeting the definition of
CKD, 60 had isolated proteinuria, 4 had isolated im-
paired estimated glomerular filtration rate (eGFR
<60 ml/min), and 4 had both proteinuria and impaired
eGFR. Among participants with reduced eGFR (n = 8),
mean eGFR was 40.1 ml/min (range 15.0 – 57.7 ml/
min). Among participants with proteinuria (n = 64), the
mean protein/creatinine ratio was 345.71 (range 151.5 –
1840.9 mg/g creatinine).
Factors associated with CKD
In unadjusted Poisson analysis, older age, females, resi-
dents of Lima, and those with less education, greater
levels of insulin resistance, diabetes, and hypertension
were associated with higher probability of having CKD
(Table 2).
In multivariable Poisson analysis, age, sex, higher
wealth index, Lima residence, and diabetes were all
independently associated with CKD (Table 2). Males had
a 66 % lower prevalence of CKD than females and par-
ticipants at the Tumbes site had a 46 % lower prevalence
than among those recruited at the Lima site. Diabetes
was associated with doubling prevalence of CKD. It is
noted that HOMA, hs-CRP, and Framingham Risk Score
were not significant in the final model.
Exploratory stratified analysis by sex and geographical
site
A higher prevalence of CKD was observed among fe-
males overall as well as within each age stratum (Table 3,
Fig. 2). Among men, the prevalence of CKD was similar
between most subgroups evaluated. The only exception
was a tendency towards a gradient of doubling preva-
lence estimates in the Framingham risk score groups
(Fig. 3, see also Additional file 1). In women, both dia-
betes and hypertension were associated with double the
prevalence of CKD contrasted to those without these
conditions (Fig. 3, see also Additional file 1).
CKD prevalence was higher (p-value = 0.04) in Lima
(21 %) than in Tumbes (13 %). Females, having diabetes,
and hypertension were significantly associated with
higher CKD prevalence in both sites (Fig. 4, see also
Additional file 1).
Discussion
In this representative cross-sectional sample of Peruvian
adults from two different geographical sites, the preva-
lence of CKD was 16.8 %. These estimates are similar to
those from high-income countries. Proteinuria, rather
than reduced eGFR, was the defining factor for CKD in
the vast majority (88 %) of individuals detected to have
disease. In our sample, individuals with CKD were more
likely to be female, older, of a higher socioeconomic
stratum, diabetic and hypertensive. Compared to
Tumbes, the study population in Lima had a higher
prevalence of CKD.
Previous studies in Iran and the United States have
found CKD prevalence estimates ranging between 13–
18 %, and in Asian countries, such as China, Japan and
Korea, 14–22 % [29–33]. Although measures of CKD
prevalence in Latin America are rare [34], reports from
El Salvador and Nicaragua have estimated that 12.7 % of
these populations are afflicted with CKD [35, 36]. In
addition, a recent survey examining CKD prevalence in
Latin America reported the prevalence of proteinuria in
Mexico and Chile to be 9.2 % and 14.2 %, respectively
[37]. Notably, the definition of CKD used in these stud-
ies has varied including differences in thresholds defin-
ing proteinuria and eGFR, in equations used to calculate
eGFR, and in the reliance on eGFR and proteinuria to
define CKD. We defined CKD in accordance with other
epidemiological studies by considering functional
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Table 1 Characteristics of participants with and without chronic kidney disease (CKD) in CRONICAS-CKD pilot study
No CKD CKD p-value
n = 336, 83.1 % n = 68, 16.8 %
Median (IQR) or Median (IQR) or
n (%) n (%)
Sociodemographics
Age, year 53.5 (43.6–63.2) 59.6 (50.5–69.2) <0.01
Male, n (%) 182 (54.2) 21 (30.9) <0.01
Location, n (%)
Lima 161 (47.9) 42 (61.8) 0.04
Tumbes 175 (52.1) 26 (38.2)
Education (yrs), n (%) <0.01
Primary or less 138 (41.1) 41 (60.3)
Secondary 139 (41.4) 14 (20.6)
Higher than secondary 59 (17.6) 13 (19.1)
Wealth index, n (%) 0.17
Low 67 (19.9) 7 (10.3)
Medium 134 (39.9) 30 (44.1)
High 135 (40.2) 31 (45.6)
Smoking, n (%) 0.20
Never 158 (47.0) 40 (58.8)
Former 132 (39.3) 20 (29.4)
Current 46 (13.7) 8 (11.8)
Alcohol, n (%) 0.56
Yes 150 (44.6) 33 (48.5)
No 186 (55.4) 35 (51.5)
Comorbidities and laboratory findings
Diabetes Mellitus, n (%) 27 (8.0) 13 (19.1) <0.01
Fasting glucose, mg/dL 93 (87–101) 96 (87–109) <0.01
HbA1c, % 5.7 (5.5–6.0) 5.9 (5.6–6.4) <0.01
Hypertension, n (%) 89 (26.5) 29 (42.7) <0.01
Obesity, n (%) 112 (33.3) 22 (32.4) 0.88
Body mass index, kg/m2 28.1 (25.3–31.3) 27.3 (24.3–31.1) 0.55
Total cholesterol, mg/dL 201 (178.5–227) 203 (184–247.5) 0.06
Urine creatinine, mg/dL 100.8 (68.1–145.2) 55.4 (39.6–104.4) <0.01
Protein-creatinine ratio, mg/g 79.9 (59.7–103.7) 204.6 (169.8–324.6) <0.01
eGFR , ml/min/1.73 m2 99.8 (89.1–109.2) 98.1 (80.5–107.3) <0.01
hs-CRP mg/L 2.2 (1.0–4.3) 2.0 (1.3–4.2) 0.65
HOMA-IR 1.96 (1.15–3.35) 2.18 (1.12–3.67) 0.01
HOMA-β 102.1 (59.8–162.8) 93.2 (55.7–136.1) 0.80
Framingham risk score, n (%) 0.15
Low 166 (49.4) 25 (36.8)
Intermediate 100 (29.8) 24 (35.3)
High 70 (20.8) 19 (27.9)
eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment- insulin resistance,
HOMA-β homeostatic model assessment- β cell function, hs-CRP high sensitivity C-reactive protein, LDL low-density lipoprotein
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abnormalities, such as proteinuria, with and without
lowered eGFR and utilizing prototypical cutoff values for
both variables. We were not, however, able to incorpor-
ate the requirement of persistence of abnormalities for
greater than three months [38].
Also noteworthy is the variability in the predominating
factor defining CKD across diverse national settings-
proteinuria dominance versus eGFR dominance. For in-
stance, in Nicaragua, proteinuria was the predominant
factor seen among CKD patients; an uncommon trend
given that eGFR is usually more prominent [36]. In our
study, CKD was proteinuria driven.
Older age and female gender were independent predic-
tors of CKD among our participants, consistent with re-
ports from the United States and Iran [29, 30] but not
from Nicaragua and Sri Lanka where males had a higher
prevalence of disease. CKD prevalence was higher in pa-
tients with vascular disease risk factors like diabetes, par-
ticularly in female patients and older patients. Indeed, in
our female sample, but not in males, CKD was more
prevalent among those who had diabetes and hyperten-
sion. It is noted however that males had a higher per-
centage of diabetes and hypertension, compared to
females. The mechanisms underlying the sex difference
in CKD epidemiology and CKD progression remain un-
clear and may involve a differential impact of traditional
risk factors and environmental influences [39].
Poverty and social deprivation are documented risk
factors for the development and progression rate of
CKD in high-income countries and LMIC [40]. The sites
fall below average socioeconomic indicators for Peru
and Lima. For example, access to health insurance in
our Lima and Tumbes sites was 37 % and 50 %, respect-
ively [41]. Of note, the type of insurance reported is
likely government subsidized insurance schemes, which
cover basic services such as immunizations, maternal
health, and large infectious diseases programs such as
tuberculosis and HIV [9]. This could infer that access to
general medical care where CKD can be detected and
managed is low. Within this socioeconomic setting, and
compared to the group with lowest wealth index, we
identified a higher prevalence of CKD among participants
Table 3 Prevalence of chronic kidney diseases stratified by age categories and sex
Male Female
Age, years Case/n Estimated prevalence (95% CI) Case/n Estimated prevalence (95% CI)
35–44 3/51 5.8 (1.9–17.8) 5/51 9.8 (4.2–22.7)
45–54 5/54 9.2 (4.0–21.5) 12/51 23.5 (14.3–38.8)
55–64 6/51 11.8 (5.5–25.1) 9/48 18.8 (10.3–34.0)
≥65 7/47 14.9 (7.4–29.7) 21/51 41.2 (29.6–57.3)
Overall 21/203 10.3 (6.9–15.5) 47/201 23.4 (18.2–30.1)
p-value for trend 0.13 0.001





(95% CI) (95% CI)a
Age change by 10 years 1.47 (1.20–1.80) 1.48 (1.18–1.87)
Sex
Female 1 (reference) 1 (reference)
Male 0.38 (0.22–0.66) 0.34 (0.19–0.62)
Education
High school or less 1 (reference) 1 (reference)
More than high school 0.71 (0.41–1.24) –
Wealth Index
Low 1 (reference) 1 (reference)
Medium 2.14 (0.89–5.13) 2.57 (1.02–6.44)
High 2.20 (0.92–5.25) 2.64 (1.04–6.67)
Study site
Lima 1 (reference) 1 (reference)
Tumbes 0.57 (0.33–0.97) 0.54 (0.30–0.96)
Diabetes
No 1 (reference) 1 (reference)
Yes 2.71 (1.32–5.56) 2.21 (1.03–4.78)
Hypertension
No
Yes 2.06 (1.20–3.53) 1.38 (0.75–2.54)
HOMA-IR 1.09 (1.01–1.16) –





Low 1 (reference) –
Intermediate 1.59 (0.86–2.94) –
High 1.80 (0.93–3.48) –
aModels to calculate adjusted prevalence ratios (n = 404, no missing values)
were adjusted, where appropriate, for all of these variables: age, sex, wealth
index, study site, diabetes, and hypertension
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within the highest wealth index tertile (all wealth strata
were below the poverty line). Following significant ex-
pansion of Seguro Integral de Salud in 2009, it was
noted that among the Peruvian poor, the poorest of the
poor were insured to a greater extent than the wealthier
of the poor [Ref is same as the new ref inserted in Intro].
Perhaps this subgroup accessed care that lessened the
extent of CKD risk factors or, perhaps survival bias con-
tributed to the trend. This difference, however, was not
observed by education level.
CKD prevalence was higher in Lima than in Tumbes
by nearly two-fold. This difference could be partly related
to the higher prevalence of diabetes and hypertension,
among patients with CKD, in Lima compared to Tumbes.
Fig. 2 Prevalence of chronic kidney disease stratified by sex and age
Fig. 3 Differences between persons with and without chronic kidney disease stratified by sex
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It has been suggested that certain environmental factors
promote CKD, including pesticide exposure, and
others slow progression of CKD, including high alti-
tude [35, 42, 43]. We were not able to directly examine
either of these attributes in this study. More specifically,
high altitude has been associated with higher levels of
eGFR [43]. Though Lima and Tumbes are both approxi-
mately at sea level, nearly 50–60 % of the population at
the Lima site are within-country migrants originating
largely from high altitude Andean locations [41]. This
might partially explain the smaller number of individ-
uals in Lima with low eGFR and their higher average
eGFR, compared to Tumbes. However, the reasons for
the two-fold greater number of participants with pro-
teinuria in Lima compared to Tumbes are unclear.
Study strengths and limitations
The strengths of this study include high-quality data col-
lection methods and surveillance of disease outcomes,
all nested in a well-designed population-based study, a
high response rate within the ancillary CKD component
of the larger study, and standardized laboratory methods
for measuring renal biomarkers. However, the study also
had several limitations. First, while the cross-sectional
design of this study provided the opportunity to estimate
CKD prevalence in two Peruvian sites, causal relation-
ships between CKD and measured risk factors cannot be
determined. Further, not all potential risk factors were
measured such as environmental exposures and health
care accessibility. Second, misclassification of CKD sta-
tus could not be excluded as we relied on a single meas-
urement of kidney biomarkers rather than multiple
measurements over time. Third, the sample size was
moderate and may not have been sufficient for detection
of small-to-moderate effects of hypothesized risk factors.
Finally, some information biases related to the nature of
the study cannot be discounted, such as temporal ambi-
guity and lead time biases [44].
Conclusions
In summary, this study has identified a high prevalence,
most likely undiagnosed, of CKD in Lima and Tumbes.
This trend may or may not be representative of CKD
throughout Peru. CKD’s silent progression, its associ-
ation with cardiovascular disease, and high treatment
costs make this disease one of great public health con-
cern. As such, every effort should be made to expand
upon this study through larger nationwide surveillance
efforts. This will inform policies aimed at preventing
CKD from escalating in Peru, especially given that renal
replacement therapy is out of financial reach for the ma-
jority of Peruvians under their current health care sys-
tem. These actions would pave the way for interventions
aimed at reducing CKD prevalence and effectively man-
aging existing cases of disease.
Fig. 4 Differences between persons with and without chronic kidney disease stratified by geographical site
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Additional file
Additional file 1: Estimated prevalence of CKD and 95 %
confidence interval by participants’ comorbidities stratified by sex
and by area.
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